Last reviewed · How we verify

Ibuprofen plus caffeine

Mantecorp Industria Quimica e Farmaceutica Ltd. · Phase 3 active Small molecule

Ibuprofen inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis and inflammation, while caffeine enhances analgesic efficacy and reduces drowsiness.

Ibuprofen inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis and inflammation, while caffeine enhances analgesic efficacy and reduces drowsiness. Used for Acute pain relief (headache, migraine, dental pain, musculoskeletal pain).

At a glance

Generic nameIbuprofen plus caffeine
SponsorMantecorp Industria Quimica e Farmaceutica Ltd.
Drug classNSAID with adjuvant analgesic
TargetCOX-1, COX-2; adenosine receptors
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that blocks COX-1 and COX-2 enzymes, thereby decreasing prostaglandin production and providing anti-inflammatory, analgesic, and antipyretic effects. Caffeine acts as an adenosine receptor antagonist and enhances the analgesic potency of ibuprofen, allowing for lower doses and faster pain relief while also counteracting potential sedation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results